Methods for treating delaying the progression of alzheimer's disease with heterocyclic compounds

Abstract

Disclosed is an antidepressant, neuroprotectant, amyloid β deposition inhibitor, or age retardant composition containing a heterocyclic compound having the general formula (I):

1 . A method of delaying the progression of Alzheimer's disease in a human in need thereof, comprising administering to the human an effective amount of a compound having the general formula (I):  
       
         
           
           
               
               
           
         
         or a pharmaceutically acceptable salt or hydrate thereof, wherein:  
         in the general formula (I), the structural unit having the general formula (II):  
         
           
             
             
                 
                 
             
           
         
         is one or more structural units selected from multiple types of structural units having the general formula (III):  
         
           
             
             
                 
                 
             
           
         
         in the general formula (I),  
         R 1  and R 2  each are one or more functional groups independently selected from the group consisting of a hydrogen atom, halogen atom, hydroxy group, amino group, acetylamino group, benzylamino group, trifluoromethyl group, C 1 -C 6  alkyl group, C 1 -C 6  alkoxy group, and —O—(CH 2 )n—R 5 , wherein R 5  is a vinyl group, C 3 -C 6  cycloalkyl group, or phenyl group, and n is 0 or 1;  
         R 3  and R 4  each are one or more functional groups independently selected from the group consisting of a hydrogen atom, C 1 -C 6  alkyl group, C 3 -C 8  cycloalkyl group, and —CH(R 7 )—R 6 ; alternatively, R 3  and R 4  together form a spiro ring having the general formula (IV):  
         
           
             
             
                 
                 
             
           
         
         said R 6  is one or more functional groups selected from the group consisting of a vinyl group; ethinyl group; phenyl optionally substituted by a C 1 -C 6  alkyl group, C 1 -C 6  alkoxy group, hydroxy group, 1 or 2 halogen atoms, di C 1 -C 6  alkylamino group, cyano group, nitro group, carboxy group, or phenyl group; phenethyl group; pyridyl group; thienyl group; and furyl group;  
         said R 7  is a hydrogen atom or C 1 -C 6  alkyl group;  
         in the general formula (IV), the structural unit B is one or more structural units selected from multiple types of structural units having the general formula (V):  
         
           
             
             
                 
                 
             
           
         
         said structural unit B binds at a position marked by * in the general formula (V) to form a spiro ring; and  
         R 8  is one or more functional groups selected from the group consisting of a hydrogen atom, halogen atom, hydroxy group, C 1 -C 6  alkoxy group, cyano group, and trifluoromethyl group.  
       
     
     
         2 . The method according to  claim 1  wherein said heterocyclic compound is spiro[imidazo[1,2-a]pyridin-2(3H)-one-3,2′-indan].  
     
     
         3 . The method according to  claim 1  or  2  wherein said administration is oral.